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group. However, there is no signiﬁcant difference between
the costs of bone fracture in older women with early
breast cancer and older women who do not have breast
cancer.
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OBJECTIVES: The decision to decide for operating liver
metastases in colorectal cancer (CRC) patients depends
largely on the performance of imaging techniques. A more
sensitive and speciﬁc test is only of value when it induces
a change in therapeutical decisions. This study aimed at
analysing the health economic impact of Resovist®, a
superparamagnetic iron oxide used in magnetic resonance
imaging (MRI) for the diagnosis of hepatic CRC metas-
tases. The selected setting was Belgium. METHODS: A
medical decision tree model simulating a patient’s evolu-
tion applying a 5-year time horizon was developed using
2 scenarios; 1) current diagnostic algorithms; and 2)
Resovist® added to current algorithms). Clinical data
reveal that, in comparison to current diagnosis Resovist®
offers an increased sensitivity (95.4 vs. 74.3 %) and a
moderately increased speciﬁcity (89.4 vs. 86.2 %), and
such an improved test performance would change medical
management in about 30% of patients. A Delphi panel
with 16 members indicated that this change in practice
would be in 29 % from no operation to operation and in
71% from operation to no operation. The Delphi panel
also provided medical resource use data. Costs of medical
resources were obtained from the public health insurance.
Life expectancy in function of chosen medical action was
obtained from epidemiological literature. RESULTS:
Resovist® increased costs with €655.4, and adds 1.32
months to life resulting in a cost-effectiveness = €5958 per
Life Year Gained, which means good value for money.
Sensitivity analysis (20% up and down) on performance
of the diagnostic tool, cost of treatment options and
change in medical practice showed robustness of the con-
clusions with a maximal range from €3527 to €10,032.
CONCLUSION: This medical decision tree approach
showed that Resovist® has the potential to improve
medical management and outcomes at a very acceptable
ratio between costs and effects.
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OBJECTIVES: Since May 2001, vinorelbine has been
available to be administered in oral form at home in the
treatment of non-small cell lung cancer. Its efﬁcacy is
similar to that of IV vinorelbine, gastro-intestinal toxic-
ity is more frequent. The periodicity of the treatment
follow up in a hospital environment is poorly deﬁned.
The aim of this study is to establish the regimen, which
minimises costs whilst ensuring patient safety. ME-
THODS: A model was constructed in order to follow 
the repercussions of attending hospital every 3, 6, or 9
weeks compared to purely outpatient, weekly manage-
ment. The corresponding costs were compared to those
of conventional treatments used in the indication: 
gemcitabine, docetaxel and paclitaxel. Costs were esti-
mated from the society perspective. For hospital courses,
the DRG costs were adjusted by replacing the drugs com-
ponent by the actual cost of the substances. For the oral
form, primary care costs are allocated values using the
price of oral form and the primary care visit or an hos-
pital specialist consultation. RESULTS: For equivalent
therapeutic efﬁcacy, oral vinorelbine appears to be the
least expensive substance: its annual follow up costs 
per patient using specialised consultations every 3, 6, 
and 9 weeks were €6360, €6190, and €5940. The least
expensive regimen was the regimen involving entirely
home management following initial day hospitalisation:
€5940. IV cytotoxic agents administered in hospital: gem-
citabine, vinorelbine, docetaxel and paclitaxel had annual
follow up costs of 6970, €7400, €8320, and €9440
respectively. CONCLUSION: How can patient safety and
the will to keep a patient at home at the end of their life
be reconciled? An economic analysis can quantify the
ﬁnancial repercussions of the more or less extensive inter-
pretations which clinicians place on the principle of 
precaution.
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Capecitabine (Xeloda®) was the ﬁrst oral oncology drug
launched on the French market for the management of
metastatic colorectal cancer patients. This drug gives the
opportunity to caregivers to treat cancer on an outpatient
basis. OBJECTIVE: Assess the economic impact of
capecitabine compared with the FuFol/Mayo Clinic
chemotherapy regimen in metastatic colorectal cancer
from the French payer’s perspective. METHODS: A RCT
(SO 14796) demonstrated an equivalent efﬁcacy of the
two therapeutic strategies. Based on this clinical data, a
cost minimisation analysis was carried out. Costs were
assessed for hospitalisation, chemotherapy regimen
administration, management of adverse events and
patient monitoring. All these costs, with the exception 
